Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.894,30
-0,16%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Myriad Genetics Inc (MYGN) Myriad Genetics Inc (MYGN) Notizie

Myriad Genetics Inc

MYGN
19,43
0,21 (1,09%)
03 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
30/4/202422:05GLOBEMyriad Genetics to Release First Quarter 2024 Financial..
17/4/202414:00GLOBENearly Half of Americans Say They’ve Lost Time in Their..
16/4/202415:15GLOBENew Myriad Genetics Study Published in Prenatal Diagnosis..
09/4/202414:00GLOBEMyriad Genetics Research Shows Reduction in Hospitalizations..
22/3/202402:40GLOBEMyriad Genetics Announces Foundational Patent Granted for..
20/3/202421:05GLOBEMyriad Genetics Announces Patent Granted for SneakPeek® Snap..
04/3/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202414:31EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202422:05EDGAR2Form 8-K - Current report
27/2/202422:05GLOBEMyriad Genetics Reports Strong Fourth Quarter and Full-Year..
27/2/202415:15GLOBEMyriad Genetics and National Cancer Center Hospital East in..
26/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202422:05GLOBEMyriad Genetics to Release Fourth Quarter and Full Year 2023..
15/2/202422:05GLOBEMyriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as..
14/2/202422:47EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202414:24EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202416:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202415:25GLOBEMyriad Genetics Completes Acquisition of Precise Tumor,..
31/1/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202423:00GLOBEMyriad Genetics Names George Daneker Jr., MD, as President..
29/1/202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202422:21EDGAR2Form 3 - Initial statement of beneficial ownership of..
23/1/202422:31EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
22/1/202420:03EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
19/1/202400:10GLOBEMyriad Genetics to Acquire Precise Tumor, Precise Liquid and..
16/1/202415:00EDGAR2Form 8-K - Current report
09/1/202422:05GLOBEMyriad Genetics Applauds New Germline Testing Guideline for..
03/1/202422:05GLOBEMyriad Genetics to Present at 42nd Annual J.P. Morgan..
02/1/202423:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202314:30EDGAR2Form 8-K - Current report
21/12/202314:30GLOBEMyriad Genetics Chief Financial Officer Bryan Riggsbee..
20/12/202314:00GLOBEMyriad Genetics Establishes Comprehensive Pan-Cancer..
12/12/202300:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202300:34EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/12/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202322:05GLOBEMyriad Genetics Celebrates One Million SneakPeek® Results..
16/11/202322:05GLOBEMyriad Genetics and Personalis Partner to Market..
13/11/202322:31EDGAR2Form 8-K - Current report
13/11/202312:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/11/202313:00GLOBEMyriad Genetics to Participate in Stephens Annual Investment..
09/11/202303:20GLOBEMyriad Genetics Announces Pricing of Upsized Offering of..
09/11/202303:16EDGAR2Form 8-K - Current report
08/11/202322:10GLOBEMyriad Genetics Announces Proposed Offering of $100 Million..
08/11/202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/11/202322:01EDGAR2Form S-3ASR - Automatic shelf registration statement of..
07/11/202314:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202322:05EDGAR2Form 8-K - Current report
06/11/202322:05GLOBEMyriad Genetics Reports Third Quarter 2023 Financial..
03/11/202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 19,85 Min: 19,40 Max: 20,09
Chiusura: 19,22

La tua Cronologia

NASDAQ
MYGN
Myriad Genetics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network